MD Magazine (3/5, Walter) reports, “The response rate of antidepressant medications can be low when pharmacogenomics are not taking into account for patients suffering from major depressive disorder (MDD),” researchers concluded after examining “the success of guided-care compared to common treatment for major depressive disorder in a 24-week, randomized, controlled” study called “The Genomics Used to Improve DEpression Decisions (GUIDED) trial.” The study “included 1167 outpatient diagnosed with” MDD. The findings were published last April in the Journal of Psychiatric Research.
Related Links:
— “Pharmacogenomics Effective for Major Depressive Disorder Patients, “Kenny Walter, MD Magazine, March 5, 2020